These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27742709)

  • 1. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
    Rajkumar SV; Harousseau JL
    Blood; 2016 Dec; 128(24):2757-2764. PubMed ID: 27742709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and clinical impact of multiple myeloma to managed care.
    Cook R
    J Manag Care Pharm; 2008 Sep; 14(7 Suppl):19-25. PubMed ID: 18774882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):839-54. PubMed ID: 22716498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.
    Ailawadhi S; DerSarkissian M; Duh MS; Lafeuille MH; Posner G; Ralston S; Zagadailov E; Ba-Mancini A; Rifkin R
    Clin Ther; 2019 Mar; 41(3):477-493.e7. PubMed ID: 30773308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guideline Adherence Regarding the Use of Expensive Drugs in Daily Practice: The Examples of Trastuzumab in Breast Cancer and Bortezomib in Multiple Myeloma.
    Boons CC; Wagner C; Hugtenburg JG
    Oncol Res Treat; 2016; 39(7-8):417-22. PubMed ID: 27486994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
    Dranitsaris G
    Int J Technol Assess Health Care; 1999; 15(1):108-22. PubMed ID: 10407599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value and Cost of Myeloma Therapy.
    Rajkumar SV
    Am Soc Clin Oncol Educ Book; 2018 May; 38():662-666. PubMed ID: 30231405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
    Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
    Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?
    Aguiar PM; Lima TM; Storpirtis S
    J Clin Pharm Ther; 2016 Apr; 41(2):189-97. PubMed ID: 27009796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
    Kim MY; Sposto R; Swaika A; Asano H; Alamgir A; Chanan-Khan A; Ailawadhi S
    Oncology; 2014; 87(4):224-31. PubMed ID: 25059308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.
    Touati M; Lamarsalle L; Moreau S; Vergnenègre F; Lefort S; Brillat C; Jeannet L; Lagarde A; Daulange A; Jaccard A; Vergnenègre A; Bordessoule D
    Support Care Cancer; 2016 Dec; 24(12):5007-5014. PubMed ID: 27525991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
    Gooding S; Lau IJ; Sheikh M; Roberts P; Wong J; Dickens E; Bullement A; Elvidge J; Lee D; Ramasamy K
    PLoS One; 2015; 10(9):e0136207. PubMed ID: 26367874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
    Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations.
    Wisløff F; Gulbrandsen N; Nord E
    Pharmacoeconomics; 1999 Oct; 16(4):329-41. PubMed ID: 10623362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
    Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
    J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic research and clinical trials: concepts and issues.
    Bootman JL; Larson LN; McGhan WF; Townsend RJ
    DICP; 1989 Sep; 23(9):693-7. PubMed ID: 2800585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.